NASDAQ: VALNValneva Se Stock
$6.79+0.22 (+3.35%)
Updated Apr 17, 2025
VALN Price
$6.79
Fair Value Price
N/A
Market Cap
$551.34M
52 Week Low
$3.62
52 Week High
$9.50
P/E
-39.02x
P/B
2.8x
P/S
1.72x
PEG
N/A
Dividend Yield
N/A
Revenue
$184.33M
Earnings
-$12.76M
Gross Margin
41.9%
Operating Margin
7.37%
Profit Margin
-7.2%
Debt to Equity
1.76
Operating Cash Flow
-$68M
Beta
1.04
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
VALN Overview
Valneva SE develops prophylactic vaccines for infectious diseases. Offerings include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine, DUKORAL, an oral vaccine for the prevention of diarrhea, and VLA2001, a vaccine candidate for SARS-CoV-2. Valneva SE collaborates with Pfizer to co-develop its Lyme disease vaccine and Instituto Butantan for the manufacturing of a single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VALN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VALN
Ranked#109 of 463
Ranked#109 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important VALN news, forecast changes, insider trades & much more!
VALN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VALN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VALN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VALN is good value based on its book value relative to its share price (2.8x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
VALN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more VALN due diligence checks available for Premium users.
Valuation
VALN fair value
Fair Value of VALN stock based on Discounted Cash Flow (DCF)
Price
$6.79
Fair Value
-$5.31
Undervalued by
227.89%
VALN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VALN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-39.02x
Industry
-177.72x
Market
27.98x
VALN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.8x
Industry
4.05x
VALN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VALN's financial health
Profit margin
Revenue
$55.1M
Net Income
-$38.5M
Profit Margin
-69.9%
VALN's Earnings (EBIT) of $13.58M... subscribe to Premium to read more.
Interest Coverage Financials
VALN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$520.9M
Liabilities
$332.1M
Debt to equity
1.76
VALN's short-term assets ($325.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VALN's short-term assets ($325.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VALN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
VALN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$11.5M
Investing
$4.9M
Financing
-$4.8M
VALN's operating cash flow (-$71.38M)... subscribe to Premium to read more.
Debt Coverage Financials
VALN vs Biotech Stocks
Valneva Se Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.